4DMedical commences scanning in US at Providence St. Joseph
Filed with ASX · · 2 pages · English
• 4DMedical’s XV LVAS™software is being used to assist in screening for multiple respiratory conditions, including Chronic Obstructive Pulmonary Disease (COPD) and long-COVID • Clinical pilots form an important part of 4DMedical’s commercialisation strategy, allowing institutions to implement and trial the Company’s end-to-end solution ahead of potential commercial integration Melbourne, Australia
Earlier from 4DMedical
- 4DMedical Reports 1H FY22 Results
- Quarterly Activity Report and Appendix 4C for Q2 FY2022
- First commercial scans with I-MED to commence in December
- 2021 Annual General Meeting presentation
- Quarterly Activity Report and Appendix 4C for Q1 FY2022
Later from 4DMedical
- Quarterly Activity Report and Appendix 4C for Q3 FY2022
- 4DMedical clinical trial results presented at ATS
- 4DMedical secures national contract with I-MED
- Quarterly Activity Report and Appendix 4C for Q4 FY2022
- Amended Quarterly Activity Report & Appendix 4C - Q4 FY2022
Follow 4DMedical into a list and get an email when it puts out news.
Follow 4DMedical